CSL Limited and National Blood Authority sign new Australian Fractionation Agreement

CSL Limited and National Blood Authority sign new Australian Fractionation Agreement

Melbourne, Australia — 23/12/2009

CSL Limited (ASX: CSL) announced today that it has signed an agreement with the National Blood Authority, acting on behalf of both State and Commonwealth Governments, to continue to provide the Australian community with safe, secure and affordable plasma therapeutic products. 

“CSL welcomes the opportunity to continue our longstanding commitment to provide plasma derived therapeutic products for use by Australians living with serious medical conditions”, Managing Director and Chief Executive Officer of CSL Limited, Dr Brian McNamee said today.

“The Agreement provides the Australian public with a secure supply of plasma derived medicines of the highest safety and quality over the life of the Agreement”, he said.


Download the full release:
CSL Limited and National Blood Authority sign new Australian Fractionation Agreement (0.09MB)


For further information, please contact:

Pippa McIntosh
Senior Communications Manager
CSL Limited
Phone: +61 3 9389 1756
Email: pippa.mcIntosh@csl.com.au
© 2016 CSL Limited